A Study of ENMD-2076 in Ovarian Clear Cell Cancers

• ClinicalTrials.gov Identifier: NCT01914510
• Recruitment Status: Completed
• First Posted: August 2, 2013
• Results First Posted: December 13, 2019
• Last Update Posted: December 13, 2019
• Sponsor: University Health Network, Toronto
• Information provided by (Responsible Party): University Health Network, Toronto

Study Description

Brief Summary:

This is a phase 2 study to see how useful, safe, and tolerable an investigational drug called ENMD-2076 is in treating patients with ovarian clear cell carcinomas.

ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A and tyrosine kinase from working. These enzymes are needed for cells to divide including cancer cells. ENMD-2076 also works by stopping the growth of new blood vessels which would provide the tumor with nutrients for it to grow. It is believed that by blocking Aurora A and tyrosine kinase enzymes from working and stopping new blood vessels from growing, the tumors may stop growing or shrink.

Condition or disease	Intervention/treatment	Phase
Ovarian Clear Cell Carcinoma	Drug: ENMD-2076	Phase 2

Detailed Description:

During the study, participants will be asked to take ENMD-2076 once a day, everyday. Every 28 days will be called a cycle. While receiving the study drug, participants will be asked to visit the clinic for tests and procedures. During Cycle 1, participants will be asked to visit the clinic about once a week and during Cycle 2 and future cycles, participants will be asked to visit the clinic on days 1 and 15. As a part of the study, tumor tissue (archival and fresh tumor biopsy) will be taken for biomarker research. When participants stop the study drug, they will be asked to have an end of study drug visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
• Study Start Date: September 2013
• Actual Primary Completion Date: January 2017
• Actual Study Completion Date: January 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: ENMD-2076; ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.	Drug: ENMD-2076

Outcome Measures

Primary Outcome Measures :

1. Six Month Progression Free Survival Rate [ Time Frame: Response will be determined based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. Progression free survival is the time from the first day of treatment to the first observation of disease progression or Death/last F/U. ]
   Progression Free Survival (PFS) is defined as the time from first day of treatment to the first observation of disease progression or death due to any cause or last follow up. PFS will be censored for patients who are alive and free of progression at time of last follow-up.
2. Complete or Partial Response Rate [ Time Frame: 2 years ]
   Percentage of patients with complete or partial response as per RECIST 1.1 criteria.

Secondary Outcome Measures :

1. Time to Disease Progression [ Time Frame: 2 years ]
   Length of time until disease progression in patients treated with ENMD-2076
2. Levels of Certain Proteins and Gene Expression Compared to Patient Outcome Following Treatment [ Time Frame: 2 years ]
   Association of somatic mutations in PIK3CA, ARID1A and PTEN mutation status, and ARID1A and PTEN expression assessed in archival samples and tumour biopsies with tumour response and patient outcome following treatment with ENMD 2076.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have histologically documented diagnosis of ovarian clear cell carcinoma.
• Any number of prior chemotherapy regimens will be allowed but must include 1 line of platinum based therapy, and may include chemotherapy, biologics or other targeted therapies (except for Aurora A targeted therapies).
• Meet RECIST criteria (version 1.1) within 28 days of start of treatment by having measurable disease defined as one or more lesions that can be accurately measured in one or more dimensions. Areas of previous radiation may not serve as measurable disease unless there is evidence of progression post radiation.
• At time of registration, if the patient has had previous treatment it must have been at least 4 weeks since major surgery or radiation therapy; four weeks from any other previous anti-cancer therapy including biologics. Patients must have recovered from their treatment-related events with the exception of alopecia.
• Are ≥18 years of age

• Have clinically acceptable laboratory screening results within certain limits specified below:

  • AST and ALT ≤ 2.5 times upper limit of normal (ULN) or less than or equal to 5 times ULN if liver metastases are present
  • Total bilirubin ≤ 1.5 x ULN
  • Creatinine ≤ 1.5 x UL
  • Absolute neutrophil count ≥ 1500 cells/mm
  • Platelets ≥ 150,000/mm3
  • Hemoglobin ≥ 9.0 g/dl
• Have an ECOG performance status of ≤ 2
• Women of child-producing potential must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential.
• Have the ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
• Able to tolerate oral medication.

Exclusion Criteria:

• Women who are pregnant or nursing
• Have active, acute, or chronic clinically significant infections or bleeding.
• Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); or history of congestive heart failure (equal to or greater than Grade 2).
• Have active angina pectoris, stroke, previous myocardial infarction within the past 12 months and not clinically stable, or any other pre-existing uncontrolled cardiovascular condition.
• Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec.
• Have additional uncontrolled serious medical or psychiatric illness.
• Require therapeutic doses of anti-coagulation with warfarin or other coumarin derivatives. However, treatment with low molecular weight heparin (LMWH) is allowed.
• Known CNS metastases
• Have any medical condition that would impair the administration of oral agents including recurrent bowel obstructions, inflammatory bowel disease or uncontrolled nausea, vomiting or diarrhea
• Have persistent 2+ protein by urinalysis (patients with 2+ proteinuria that have a spot protein:creatinine ratio of less than 0.3 may be enrolled) or a history of nephrotic syndrome
• Have an active or history of additional malignancy which in the opinion of the study doctor would make assessment of outcome difficult.
• Require treatment with drugs known to be potent inducers or inhibitors of CYP3A4 at the time of registration

Contacts and Locations

Locations

Canada, Alberta

Tom Baker Cancer Centre

Calgary, Alberta, Canada, T2N 4N2

Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 1Z2

British Columbia Cancer Agency

Vancouver, Alberta, Canada, V5Z 4E6

Canada, Ontario

London Regional Cancer Program

London, Ontario, Canada, N6A 4L6

Ottawa Regional Cancer Centre

Ottawa, Ontario, Canada, K1H 8L6

Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 2M9

Sponsors and Collaborators

University Health Network, Toronto

Investigators

• Principal Investigator: Amit Oza, M.D.; Princess Margaret Cancer Centre

More Information

• Responsible Party: University Health Network, Toronto
• ClinicalTrials.gov Identifier: NCT01914510
• Other Study ID Numbers: ENMD-2076-OCC
• First Posted: August 2, 2013
• Results First Posted: December 13, 2019
• Last Update Posted: December 13, 2019
• Last Verified: December 2019

Keywords provided by University Health Network, Toronto:

ovarian; cancer; clear cell; ENMD-2076; oral; capsule

Additional relevant MeSH terms:

Carcinoma; Adenomyoepithelioma; Adenocarcinoma, Clear Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Complex and Mixed; Adenocarcinoma